Перегляд вихідного коду сторінки A Straight Forward Tip For PDGFRA

20.0 (IBM Co., Armonk, NY, USA). All reported P-values are two-tailed and P-values less than 0.05 were considered statistically significant. Results One hundred and nine patients were T1DM (39 males and 70 females) and 18 patients were T2DM (4 males and 14 females). The median duration of diabetes was 10.1 years and 5.0 years, respectively (Table 1). Both T1DM and T2DM groups had shown the changes of anthropometric indexes between baseline and follow-up tests. In T2DM, BMI z-score had shown decreasing tendency, but there was no statistical significance. The median spot urine microalbumin/creatinine ratios at baseline and follow-up were 9.4 mg/g (IQR, 6.3-26.6 mg/g) and 13.3 mg/g (IQR, 8.6-24.8 mg/g) in T1DM, and 25.3 mg/g (IQR, 11.5-56.0 mg/g) and 17.7 mg/g (IQR, 6.2-42.0 mg/g) [http://en.wikipedia.org/wiki/PDGFRA PDGFRA] in T2DM, but there were no statistical significance. The other profiles include HbA1c shown no statistical significance. Table 1 Anthropometric and laboratory characteristics of patients with type 1 and type 2 diabetes The prevalence of microalbuminuria at baseline and follow up were 21.1% and 17.4% in T1DM, and 44.4% and 38.9% in T2DM (Fig. 1). Patients were divided into 4 groups based on results of repeated microalbuminuria measurements; persistent, regression, progression of microalbuminuria and normoalbuminuria groups. In 109 T1DM patients, 23 patients had microalbuminuria at baseline, of them 13 (56.5%) had regression of microalbuminuria, 10 (43.5%) had persistent microalbuminuria, and 86 patients had [http://www.selleckchem.com/products/BIBW2992.html Afatinib cell line] no microalbuminuria at baseline, of them 9 (10.5%) showed progression of microalbuminuria during follow-up period. In 18 T2DM patients, 3 (37.5%) had regression of microalbuminuria, 5 (62.5%) had persistent microalbuminuria, and 2 (20.0%) had progression of microalbuminuria. Seventy-seven patients (89.5%) in T1DM and 8 patients (80.0%) in T2DM had negative results of microalbuminuria during follow-up. [http://www.selleckchem.com/products/Dasatinib.html learn more] Fig. 1 Schematic representation of diabetic patients with persistent, regression, and progression groups to microalbuminuria. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. Clinical characteristics and laboratory parameters of T1DM and T2DM patients were compared among persistent, regression, progression, and normoalbuminuria groups (Tables 2,?,3).3). The duration of diabetes was not different among 4 groups in T1DM (P=0.353 at baseline, P=0.455 at follow-up). In T2DM, no difference of duration of diabetes was also observed among 4 groups at baseline (P=0.861), and at follow-up (P=0.366). In T1DM, follow-up duration of microalbuminuria was longer in regression group compared to persistent (P